The reconfigured Sartobind membrane adsorber capsules from Sartorius Stedim Biotech is said to have higher binding capacities, reduced void volumes, as well as consume less buffer, enabling lower operational costs.
Sartorius Stedim Biotech (SSB) has reconfigured its Sartobind membrane chromatography capsules to enable better recovery of large molecular weight proteins, such as blood factors and conjugated proteins or viruses and virus-like particles. A range of capsule sizes with a 4 mm bed height is now available from the 1 mL nano unit up to the new 2.5 L jumbo version.
The capsules’ upstream flow channels have been optimized, and an internal core forms a miniaturized downstream channel, resembling that in existing 8 mm bed height capsules. The new Q, S and salt-tolerant STIC PA ion exchanger capsules, all with a 4 mm bed height, increase dynamic binding capacity by approximately 15% and reduce void volumes by approximately 40% compared with their predecessors, while maintaining high flow rates of 10 to 30 membrane volumes per minute.
According to SSB, Sartobind reduces operational costs by improving breakthrough behavior, making subsequent polishing steps to remove DNA, HCP, aggregates and viruses from recombinant proteins more reliable, and using less buffer.
“Traditionally, membrane adsorbers have been using available filter housings, often ignoring chromatographic process parameters, such as back-mixing effects and elution volumes. This new generation of membrane adsorber capsules takes these specific requirements into account and reflects substantial progress for bind and elute applications,” commented Dr. Fischer-Frühholz, membrane chromatography expert at SSB.
SSB has also added new 400 mL and 800 mL Sartobind Q, S and Phenyl capsules with an 8 mm bed height to its portfolio. These optimized capsules increase dynamic binding capacity up to 48% when compared to adsorbers installed in filter housings.
Source: Sartorius Stedim Biotech
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.